Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acusphere, Inc. (ACUS)
Watertown, MA, US
Acusphere, Inc. is a pharmaceutical firm specializing in the creation and market launch of cardiovascular treatments. Its flagship product is Imagify (perflubutane polymer microspheres), a cardiovascular medication designed to assess myocardial perfusion and aid in the diagnosis of coronary artery disease. This drug is administered as an injectable suspension. Initially established as Polymers For Medicine, Inc., the organization rebranded as Acusphere, Inc. in March 2004. Founded in 1993, the company maintains its headquarters in Watertown, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.96% | -99.97% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+49.8% ★ Q3'08: -49.2% (vs Q3'07)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+43.1% ★ Q3'08: +28.1% (vs Q3'07)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1,899.4% Q3'08: -1,970.2% (vs Q3'07)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1,977.0% Q3'08: -2,931.0% (vs Q3'07)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-330.4% Q3'08: +3,937.1% (vs Q3'07)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+54.5% Q3'08: +2.2% (vs Q3'07)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.40× Q3'08: -0.45× (vs Q3'07)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2009 actual |
Dec 2010 actual |
|---|---|---|
| Revenue |
1.50M
est.
|
1.00M
est.
|
| EBITDA |
-900.0K
est.
|
-600.0K
est.
|
| EBIT |
-900.0K
est.
|
-600.0K
est.
|
| Net Income |
—
est.
|
—
est.
|
| SGA |
5.42M
est.
|
3.62M
est.
|
| EPS |
—
est.
|
—
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (ii) | 2.83M | 6.10% | — | 2.83M | — | 2.83M | CO | Bermuda | 2007-07-03 | ↗ |
| 2 | Peter David Boone | 1.83M | 8.40% | 1.83M | — | 1.83M | — | IN | Canadian | 2006-02-15 | ↗ |
| 3 | PHILIP TIMON | 1.62M | 5.60% | 1.62M | — | 1.62M | — | IN | AMERICA | 2006-04-17 | ↗ |
| 4 | Burr, Egan, Deleage & Co. 04-2758272 | 901.2K | 6.30% | 901.2K | 901.2K | 901.2K | 901.2K | IA | Massachusetts | 2004-02-12 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008-07-25 | Gyenes Lawrence A | Officer | P-Purchase | A | Stock Option (Right to Buy) | 51,239 | 0.56 | 28.7K | 51,239 | — | ↗ |
| 2008-02-01 | Gyenes Lawrence A | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.57 | 114.0K | 200,000 | — | ↗ |
| 2007-11-15 | Gyenes Lawrence A | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 1.15 | 230.0K | 200,000 | — | ↗ |
| 2007-10-01 | Gyenes Lawrence A | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-08-28 | THERO JOHN F | Other | M-Exempt | A | Common Stock | 70,000 | 0.84 | 58.8K | 91,504 | — | ↗ |
| 2007-02-07 | THERO JOHN F | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 2.60 | 182.0K | 70,000 | — | ↗ |
| 2006-02-01 | THERO JOHN F | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 5.84 | 408.8K | 70,000 | — | ↗ |
| 2005-09-01 | THERO JOHN F | Officer | J-Other | A | Common Stock | 252 | 4.76 | 1.2K | 21,504 | — | ↗ |
| 2005-05-13 | THERO JOHN F | Officer | P-Purchase | A | Common Stock | 1,000 | 4.00 | 4.0K | 21,252 | — | ↗ |
| 2005-03-01 | THERO JOHN F | Officer | J-Other | A | Common Stock | 252 | 4.75 | 1.2K | 20,252 | — | ↗ |
| 2005-02-01 | THERO JOHN F | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 6.13 | 306.5K | 50,000 | — | ↗ |
| 2004-07-06 | THERO JOHN F | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 0.84 | 8.4K | 70,000 | — | ↗ |
| 2004-06-10 | BANK OF AMERICA VENTURES | 10% Owner | A-Award | A | Options (Right to Buy) | 25,000 | 6.14 | 153.5K | 25,000 | — | ↗ |
| 2004-06-03 | THERO JOHN F | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 0.84 | 8.4K | 0 | — | ↗ |
| 2004-05-11 | MCGUIRE TERRANCE | Director | J-Other | D | Common Stock | 421,379 | 6.67 | 2.81M | 1,099,946 | — | ↗ |
| 2004-02-10 | THERO JOHN F | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 9.60 | 576.0K | 60,000 | — | ↗ |
| 2003-10-14 | MCGUIRE TERRANCE | Director | C-Conversion | D | Series J-2 Convertible Preferred Stock | 1,445,597 | 0.00 | — | 0 | — | ↗ |
| 2003-10-14 | BANK OF AMERICA VENTURES | 10% Owner | C-Conversion | D | Series I-2 Convertible Preferred Stock | 110,666 | 0.00 | — | 0 | — | ↗ |
| 2003-10-07 | MCGUIRE TERRANCE | Director | — | I | Series F-2 Convertible Preferred Stock | 34,781 | 0.00 | — | 0 | — | ↗ |
| 2003-10-07 | BANK OF AMERICA VENTURES | 10% Owner | — | I | Series F-2 Convertible Preferred Stock | 217 | 0.00 | — | 0 | — | ↗ |
| 2003-10-02 | THERO JOHN F | Officer | — | D | Stock Option (Right to Buy) | 11,361 | 13.02 | 147.9K | 0 | — | ↗ |
| 2003-03-03 | THERO JOHN F | Officer | — | D | Stock Option (Right to Buy) | 90,000 | 0.84 | 75.6K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William I. Ramage D.Phil | Chief Development Officer | 225.1K | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACUS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
